THE 60-SECOND GUIDE
Ipamorelin
Limited human evidence.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
Ipamorelin is an experimental growth-hormone secretagogue that stimulates the ghrelin-receptor pathway. Its early reputation for selective hormone release should be distinguished from evidence about clinical benefit and long-term safety in people. [1]
Potential benefits
Early pharmacology established growth-hormone-releasing activity. Evidence does not establish broad anti-aging, muscle, recovery or body-composition benefits. [1]
Evidence & its limits
FDA cites serious adverse events, including death, in an intravenous gastric-motility study, while identifying insufficient safety information for certain other injectable routes. This does not prove the drug caused every reported event or quantify risk for other routes; it does show why selective signaling is not proof of safety. [1]
Risks & unknowns
FDA flags immune-response and peptide-quality concerns. An intravenous gastric-motility study reported serious adverse events, including death. This does not establish risk for every route, but underscores the incomplete safety record. Long-term safety for wellness use is not established. [1]
Status & scope
An experimental growth-hormone secretagogue. Hormone effects and a gastric-motility trial do not establish contemporary wellness benefits or long-term safety. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- 1998 ipamorelin paper · PubMed
- FDA compounding safety assessment
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.